The Recall Desk
HighFDA (Devices)·Z-1652-2022·Announced 2022-09-07

RT-PCR Kit Recalled Due to False Positive Test Results

Qiagen's FGFR RGQ RT-PCR Kit may produce false positive results, leading to incorrect lab reports. This could expose cancer patients to inappropriate or suboptimal treatment.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA Class II recall with increased false positive test results that could lead to inappropriate cancer treatment. No illnesses or injuries have been reported; the harm is potential only.

Plain-English summary

Qiagen Sciences LLC is recalling its FGFR RGQ RT-PCR Kit (reference 8747010), a diagnostic kit used to test for specific genetic markers. The recall affects 9 kits that were distributed to healthcare facilities in Indiana, North Carolina, Minnesota, Texas, and to international locations including Belgium, China, Germany, Jordan, Italy, Netherlands, Malaysia, Spain, and Thailand. The affected lots are 169047135 (expiration 12.06.2022) and 172017806 (expiration 10.11.2022).

These kits have an increased rate of false positive results, meaning the test may incorrectly indicate the presence of a genetic marker when it is not actually present. False positive results could be reported by laboratories without correction, leading physicians and patients to act on inaccurate diagnostic information.

This kit is used to guide cancer treatment decisions. A false positive result could cause patients to receive inappropriate or suboptimal anti-cancer treatment and to experience unnecessary side effects from medications that would not otherwise be needed. Patients and healthcare providers should contact Qiagen Sciences LLC regarding any tests performed with these kits, and laboratories should review results from affected lots for accuracy.

The recalled product

Product
FGFR RGQ RT-PCR Kit (RUO, not IVD) REF 8747010
Manufacturer
Qiagen Sciences LLC
Hazard
  • false-positive
  • diagnostic-error
  • treatment-risk

Distribution

Distributed in 4 states:

  • IN
  • MN
  • NC
  • TX